(Q63966222)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

[Recommendations Onco-Urology 2010: Prostate cancer] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Arnauld Villers

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

6

F Cornud

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Michel Péneau

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

L Salomon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

D Azria

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C Bastide

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

P Beuzeboc

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

L Cormier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

D Eiss

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

P Eschwège

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

N Gaschignard

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

C Hennequin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

V Molinié

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

P Mongiat Artus

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

J-L Moreau

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

M Peyromaure

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

X Rebillard

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

P Richaud

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

P Rischmann

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

F Rozet

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

F Staerman

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

M Soulié

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Oncology Committee of the French Association of Urology (CCAFU)

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

20 Suppl 4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

S217-51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Recommendations for the reporting of prostate carcinoma: Association of Directors of Anatomic and Surgical Pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Standardized report for prostate biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Prostate biopsies: how many samples and how many containers? Cost effectiveness]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Recommendations for the reporting of prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Current practice of diagnosis and reporting of prostate cancer on needle biopsy among genitourinary pathologists

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Evaluation of p63 and p504s markers for the diagnosis of prostate cancer]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Gleason's score: update in 2008]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Diagnostic utility of a p63/alpha-methyl coenzyme A racemase (p504s) cocktail in ambiguous lesions of the prostate upon needle biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Standardized report for radical prostatectomy specimen]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Pathological definition and difficulties in assessing positive margins in radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Focal laser ablation for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Multiparametric magnetic resonance imaging in prostate cancer: present and future

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prostate cancer: local staging at 3-T endorectal MR imaging--early experience

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Quantitative dynamic MRI and localisation of non-palpable prostate cancer]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Magnetic resonance imaging in prostate cancer: the value of apparent diffusion coefficients for identifying malignant nodules

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Effect of dutasteride on the risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The prevention of prostate cancer--the dilemma continues

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Chemoprevention of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Diagnostic significance of PSA density adjusted by transition zone volume in males with PSA levels between 2 and 4ng/ml

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

PCA3: a molecular urine assay for predicting prostate biopsy outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Recommendations for best practice for prostate biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Repeat prostate biopsy--when, where, and how.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The continuing importance of transrectal ultrasound identification of prostatic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Dynamic Contrast-enhanced–magnetic Resonance Imaging Evaluation of Intraprostatic Prostate Cancer: Correlation with Radical Prostatectomy Specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Mortality results from a randomized prostate-cancer screening trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Screening and prostate-cancer mortality in a randomized European study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[The screening of prostate cancer in 2009: overview of the oncology committee of the French Urological Association].

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Magnetic resonance imaging and prostate cancer]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

1 reference

7 January 2021

Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Extrafascial versus interfascial nerve-sparing technique for robotic-assisted laparoscopic prostatectomy: comparison of functional outcomes and positive surgical margins characteristics.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Impact of nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH database.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Pelvic lymph node dissection in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The role of pelvic lymphadenectomy for prostate cancer--therapeutic?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Role of androgen deprivation therapy for node-positive prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Intra- and peri-operative outcomes comparing radical retropubic and laparoscopic radical prostatectomy: results from a prospective, randomised, single-surgeon study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Incidence, clinical symptoms and management of rectourethral fistulas after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Robot-assisted vs pure laparoscopic radical prostatectomy: are there any differences?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Management of male urinary incontinence after radical prostatectomy (CTMH AFU 2006 - 5/5). Prevention of incontinence and CTMH guidelines]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Does a nerve-sparing technique or potency affect continence after open radical retropubic prostatectomy?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Management of erectile dysfunction after radical prostatectomy]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Risk factors for vesicourethral anastomotic stricture after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Vesicourethral anastomotic strictures after radical retropubic prostatectomy: the experience of a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Vesicourethral anastomosis during radical retropubic prostatectomy: does the number of sutures matter?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Analysis of three different vesicourethral anastomotic techniques in laparoscopic radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The effect of postprostatectomy external beam radiotherapy on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Neo-adjuvant and adjuvant hormone therapy for localised prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Duration of androgen suppression in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Consequential late effects after radiotherapy for prostate cancer - a prospective longitudinal quality of life study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

High-intensity focused ultrasound: ready for primetime

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Control of prostate cancer by transrectal HIFU in 227 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Current status of HIFU and cryotherapy in prostate cancer--a review

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Locally ablative therapies for primary radiation failures: a review and critical assessment of the efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Is the flare phenomenon clinically significant?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Antiandrogen monotherapy: indications and results

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Methodologic lessons learned from hot flash studies

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Incidence and mortality of incidental prostate cancer: a Swedish register-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Incidental carcinoma of the prostate: an analysis of the predictors of progression

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Management of stage A prostate cancer with a high probability of progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

An analysis of watchful waiting for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Active surveillance for the management of prostate cancer in a contemporary cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Early outcomes of active surveillance for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

An analysis of men with clinically localized prostate cancer who deferred definitive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Insignificant prostate cancer and active surveillance: from definition to clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Pathological outcomes of candidates for active surveillance of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Nerve-sparing radical retropubic prostatectomy: techniques and clinical considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Indications and contraindications for nerve-sparing radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prediction of progression: nomograms of clinical utility

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Quality of life after radical prostatectomy or watchful waiting.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Surgical margins after radical prostatectomy: technical aspects and prognostic value]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Subgroup analysis of patients with localized prostate cancer treated within the Dutch-randomized dose escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Cryotherapy for localised prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Surgery of locally advanced prostate cancer]

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Intermediate-Term Potency, Continence, and Survival Outcomes of Radical Prostatectomy for Clinically High-Risk or Locally Advanced Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001)

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radical prostatectomy for clinical stage T3a disease

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Digital rectal exam following prostatectomy: is it still necessary with the use of PSA?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Changing patterns in competing causes of death in men with prostate cancer: a population based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Management of complications of androgen deprivation therapy in the older man.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

[Salvage radical prostatectomy after external radiotherapy for prostate cancer: indications, morbidity and results. Review from CCAFU prostate section].

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Salvage radical prostatectomy for radiorecurrent prostate cancer: indications and results

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Management of prostate cancer recurrence after definitive radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results.

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Salvage Radiotherapy After High-Intensity Focussed Ultrasound for Recurrent Localised Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1166-7087%2810%2970042-7

7 January 2021

10.1016/S1166-7087(10)70042-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21129644%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference